U.S. market Closed. Opens in 2 days 4 hours 5 minutes

TSHA | Taysha Gene Therapies, Inc. Stock Financials Income Statements Annual

(Stock Exchange: NASDAQ)
*Sign In to persist settings
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-31
Revenue15.45M2.50MN/AN/AN/A
Cost of Revenue1.37M2.49M492.00K9.00KN/A
Gross Profit14.08M15.00K-492.00K-9.00KN/A
Operating Expenses85.45M128.53M173.27M43.00M1.11M
Selling, General & Admin28.68M37.36M41.32M11.11M128.00K
Research & Development56.78M91.17M131.94M31.89M987.00K
Other Operating Expenses-1.58M-18.00KN/A-17.03MN/A
Operating Income-71.37M-162.45M-173.27M-43.00M-1.11M
Other Expenses / Income-40.19M-3.57M-1.26M-17.01MN/A
Before Tax Income-111.57M-166.01M-174.52M-60.01M-1.11M
Income Tax Expenses1.20M3.57M936.00K-17.01M-4.46M
Net Income-111.57M-169.58M-175.46M-43.00M-1.11M
Interest Expenses5.00M3.80M1.43M28.00KN/A
Basic Shares Outstanding116.12M43.95M37.65M17.67M36.99M
Diluted Shares Outstanding116.12M43.95M37.65M17.67M36.99M
EBITDA-70.00M-125.80M-173.09M-59.98M-1.11M
EBITDA Margin-453.06%-5,027.82%0.00%0.00%0.00%
EBIT-105.36M-162.22M-173.09M-59.98M-5.58M
EBIT Margin-681.93%-6,483.45%0.00%0.00%0.00%
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-31
An error has occurred. This application may no longer respond until reloaded. Reload 🗙